<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093729</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EXC-101</org_study_id>
    <nct_id>NCT01093729</nct_id>
  </id_info>
  <brief_title>A Study of HM11260C in Healthy Male Subject</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design.
      Five ascending dose cohorts are planned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics
      of single subcutaneous dose of HM11260C in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1, 2, 3, 4, 5, 7, 9, 16, 22, 30, 36, 43, 57, 84 Day</time_frame>
    <description>Investigate Safety of HM10560A: Safety data, including physical examinations, laboratory evaluation, ECGs, vital signs, adverse events, and immunogenicity</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 0.5mcg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 2mcg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 4mcg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 8mcg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM11260C 14mcg/kg or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C 0.5mcg/kg or Placebo</description>
    <arm_group_label>Cohort1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C 2mcg/kg or Placebo</description>
    <arm_group_label>Cohort2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C 4mcg/kg or Placebo</description>
    <arm_group_label>Cohort3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C 8mcg/kg or Placebo</description>
    <arm_group_label>Cohort4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>HM11260C 14mcg/kg or Placebo</description>
    <arm_group_label>Cohort5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, age range 20 to 45 years

          2. Weight&gt;50 and &lt; 90kg, Body mass index of &gt;18 and &lt;27 Subject is informed of the
             investigational nature of this study and voluntarily agrees to participate in this
             study

        Exclusion Criteria

          1. Acute disease within 1 month prior to start of study drug administration

          2. Has previously disease which affect drug absorption, distribution, metabolism,
             excretion (e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic
             disease, renal disease)

          3. History or presence of clinically significant and active cardiovascular, pulmonary,
             renal, endocrine, hematological, gastrointestinal, central nervous system, psychiatric
             disorder, autoimmune disease, or malignant tumor

          4. Has unsuitable clinical test results through the medical checkup, within 35 days prior
             to start of administration of study drug (medical history, physical examination, ECG,
             laboratory test)

          5. Laboratory test results

               1. AST (sGOT) or ALT (sGPT) &gt; 1.25Xupper normal limit

               2. Total bilirubin &gt; 1.5Xupper normal limit

               3. Absolute Neutrophil Count &lt; 1500 mm2

          6. History or presence of clinically significant allergic disease (including mild
             allergic rhinitis and allergic dermatitis which is not necessary to medication)

          7. Prior exposure to products related to Exenatide

          8. Use of any prescription medication within 14 days prior to Day 1

          9. Use of any medication within 7 days prior to Day 1 (over-the-counter medication,
             herbal products, nutrient, vitamins)

         10. Subject who can't eat standard meal received by Korea University Anam Hospital

         11. Donor of whole blood for transfusion within 60 days prior to start of study drug
             administration or donor of apheresis within 20 days or Receiver of blood transfusion
             within 1 month

         12. Participation in another clinical study within 60 days prior to start of study drug
             administration

         13. Taking Caffein(&gt; 5cups/ day) or alcohol abuse (&gt; 30g/ day) or excessive smoker(&gt; 10
             Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Clinical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exendin-4</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

